CMS to Cover Next-Gen Sequencing for Cancer: Implications for MCOs

 

Precision for Medicine’s David Parker and Karen Richards review the recent CMS announcement of a final national coverage determination (NCD) expanding coverage for next-generation sequencing (NGS) tests used as companion diagnostics for determining cancer patients’ eligibility for appropriately indicated drugs.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.